Clinical Trial Update: A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed (ALIMTA) plus oxaliplatin given every 21 days as first-line therapy for advanced colorectal cancer. The study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Alimta (pemetrexed)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED